Last reviewed · How we verify
Placebo eye drops of 0.5% Methylcellulose
Placebo eye drops of 0.5% Methylcellulose is a Artificial tear / Lubricating agent Small molecule drug developed by University of Campinas, Brazil. It is currently in Phase 3 development for Dry eye disease (as placebo control in Phase 3 trial). Also known as: Placebo.
Methylcellulose acts as a lubricating and viscosity-enhancing agent that mimics natural tears to provide ocular surface protection and moisture.
Methylcellulose acts as a lubricating and viscosity-enhancing agent that mimics natural tears to provide ocular surface protection and moisture. Used for Dry eye disease (as placebo control in Phase 3 trial).
At a glance
| Generic name | Placebo eye drops of 0.5% Methylcellulose |
|---|---|
| Also known as | Placebo |
| Sponsor | University of Campinas, Brazil |
| Drug class | Artificial tear / Lubricating agent |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Methylcellulose is a cellulose derivative that forms a protective film over the cornea and conjunctiva, increasing tear film viscosity and reducing evaporation. It provides mechanical lubrication and hydration to the ocular surface, helping to relieve symptoms of dry eye and protect the epithelium. As a placebo formulation in this trial, it serves as a control comparator rather than an active therapeutic agent.
Approved indications
- Dry eye disease (as placebo control in Phase 3 trial)
Common side effects
- Mild ocular irritation
- Transient blurred vision
- Foreign body sensation
Key clinical trials
- Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus (PHASE3)
- CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops (PHASE2)
- Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240) (PHASE2)
- Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells (NA)
- Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo eye drops of 0.5% Methylcellulose CI brief — competitive landscape report
- Placebo eye drops of 0.5% Methylcellulose updates RSS · CI watch RSS
- University of Campinas, Brazil portfolio CI
Frequently asked questions about Placebo eye drops of 0.5% Methylcellulose
What is Placebo eye drops of 0.5% Methylcellulose?
How does Placebo eye drops of 0.5% Methylcellulose work?
What is Placebo eye drops of 0.5% Methylcellulose used for?
Who makes Placebo eye drops of 0.5% Methylcellulose?
Is Placebo eye drops of 0.5% Methylcellulose also known as anything else?
What drug class is Placebo eye drops of 0.5% Methylcellulose in?
What development phase is Placebo eye drops of 0.5% Methylcellulose in?
What are the side effects of Placebo eye drops of 0.5% Methylcellulose?
Related
- Drug class: All Artificial tear / Lubricating agent drugs
- Manufacturer: University of Campinas, Brazil — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Dry eye disease (as placebo control in Phase 3 trial)
- Also known as: Placebo
- Compare: Placebo eye drops of 0.5% Methylcellulose vs similar drugs
- Pricing: Placebo eye drops of 0.5% Methylcellulose cost, discount & access